(Z)-4-Hydroxytamoxifen

(Z)-4-Hydroxytamoxifen

Catalog Number:
FC01365805APE
Mfr. No.:
APE-B5421
Price:
$164
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          Estrogen receptors (ER) are members of the superfamily of ligand-modulated nuclear receptors that mediate the actions of steroid hormones, vitamin D, retinoids, and thyroid hormones. ER is activated in vivo when bound by naturally occurring estrogens such as 17α-estradiol. In addition to regulating these physiological processes, estrogen also plays a central role in stimulating breast cancer growth. (Z)-Tamoxifen is a first generation selective ER modulators that is currently approved by the FDA and is widely used to treat estrogen-dependent breast cancers. Its active metabolite, (Z)-4-Hydroxytamoxifen, is a potent estrogen receptor modulator.In vitro: (Z)-4-hydroxytamoxifen binds to ER with 8-fold higher affinity than tamoxifen. It was found that only the Z isomer has the required antiestrogenic activity; the (E)-4-hydroxytamoxifen has only about 5% of its affinity for the ER [1]. In vivo: The antioestrogenic activities of (Z)-4-hydroxytamoxifen and tamoxifen were determined after oral administration. (Z)-4-hydroxytamoxifen was administered to groups of immature rats which also received s.c. injections of 0-2 μg oestradiol. Both compounds produced a dose-related decrease in uterine wet weight when compared with the oestradiol-treated controls. At a dose of 1 μg/day, the antiuterotrophic effects of (Z)-4-hydroxytamoxifen and tamoxifen were not significantly different but at 5μg/day, (Z)-4-hydroxytamoxifen was more active (P < 0.01). (Z)-4-hydroxytamoxifen therefore appears to retain its potent antioestrogenic activity after oral administration [2]. Clinical trial: Up to now, (Z)-4-Hydroxytamoxifen is still in the preclinical development stage.

          Reference:
          [1] Donna D. Yu and Barry M. Forman. Simple and Efficient Production of (Z)-4-Hydroxytamoxifen, a Potent Estrogen Receptor Modulator. J. Org. Chem. 2003, 68, 9489-9491
          [2] Jordan VC, Collins MM, Rowsby L, Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol. 1977 Nov;75(2):305-16.

      • Properties
        • Categories
          ER modulator, potent and selective
          Alternative Name
          (Z)-4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol
          CAS Number
          68047-06-3
          Molecular Formula
          C26H29NO2
          Molecular Weight
          387.51
          Purity
          98.00%
          Solubility
          ≥38.8 mg/mL in DMSO; insoluble in H2O; ≥19.63 mg/mL in EtOH
          Storage
          Store at -20°C
          SMILES
          OC1=CC=C(C=C1)/C(C(C=C2)=CC=C2OCCN(C)C)=C(C3=CC=CC=C3)\CC

          * For Research Use Only

    We Also Recommend

    AC 187

    $748

    Amylin

    $607

    Note: If you don't receive our verification email, do the following:

  • Copyright © Amerigo Scientific. All rights reserved.